Taysha Gene Therapies, Inc.
NASDAQ Global SelectTotal Valuation
Taysha Gene Therapies, Inc. carries a market capitalization of 1.28B, placing it among publicly traded companies globally. Its enterprise value stands at 1.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.28B |
| Enterprise Value | 1.82B |
Share Statistics
Taysha Gene Therapies, Inc. currently has 325.30M shares outstanding.
| Shares Outstanding | 325.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 450.68, and the price-to-book ratio stands at 5.72.
| PE Ratio | N/A |
| PS Ratio | 450.68 |
| PB Ratio | 5.72 |
| P/TBV Ratio | 5.72 |
| P/FCF Ratio | -19.19 |
| P/OCF Ratio | -18.70 |
Enterprise Valuation
| EV / Sales | 331.20 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Taysha Gene Therapies, Inc. maintains a current ratio of 17.76, meaning it holds 17.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.64, indicating elevated leverage, while an interest coverage ratio of -3,700.50 demonstrates limited ability to service its debt obligations.
| Current Ratio | 17.76 |
| Quick Ratio | 17.53 |
| Debt / Equity | 14.64 |
| Debt / EBITDA | -0.36 |
| Interest Coverage | -3,700.50 |
Financial Efficiency
| Return on Equity (ROE) | -47.05 |
| Return on Assets (ROA) | -37.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Taysha Gene Therapies, Inc.'s stock has declined approximately -16.52542% over the past 52 weeks. The 50-day moving average sits at 5.21, while the 200-day moving average is 5.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.52542% |
| 50-Day Moving Average | 5.21 |
| 200-Day Moving Average | 5.37 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Taysha Gene Therapies, Inc. generated 5.49M in revenue and converted that into -149.63M in net income, yielding earnings per share of -0.41. EBITDA reached -155.42M, while operating income came in at -156.59M.
| Revenue | 5.49M |
| Gross Profit | N/A |
| Operating Income | -156.59M |
| Pretax Income | -149.63M |
| Net Income | -149.63M |
| EBITDA | -155.42M |
| EBIT | -156.59M |
| Earnings Per Share (EPS) | -0.41 |
Balance Sheet
Taysha Gene Therapies, Inc. holds 455.41M in cash and equivalents against 56.71M in total debt, resulting in a net debt position of -406.15M. Total book value stands at 387.27M, with working capital of 435.46M providing operational flexibility.
| Cash & Cash Equivalents | 455.41M |
| Total Debt | 56.71M |
| Net Debt | -406.15M |
| Equity (Book Value) | 387.27M |
| Book Value Per Share | 1.19 |
| Working Capital | 435.46M |
Cash Flow
Taysha Gene Therapies, Inc. produced -132.19M in operating cash flow over the past twelve months. After subtracting -3.38M in capital expenditures, free cash flow totaled -135.57M - equivalent to -0.37 per share.
| Operating Cash Flow | -132.19M |
| Capital Expenditures | -3.38M |
| Free Cash Flow | -135.57M |
| FCF Per Share | -0.37 |
Margins
Taysha Gene Therapies, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,854.91 and net profit margin of -2,728.04 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -2,854.91 |
| Pretax Margin | -2,728.04 |
| Profit Margin | -2,728.04 |
| EBITDA Margin | -2,833.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.45 |
| FCF Yield | -5.21 |
Scores
Taysha Gene Therapies, Inc. posts an Altman Z-Score of 13.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.62 |